РЕКОМЕНДАЦИИ / Rekomendacii_po_diagnostike_hronich_serdech_nedostatochn_Tretii_peresmotr

307.

Al Khadra AS, Salem DN, Rand WM et al. Warfarin anticoagulation

331.

Singh SN, Poole J, Anderson J et al. Role of amiodarone or implantable

and survival: a cohort analysis from the Studies of Left Ventricular

cardioverter/defibrillator in patients with atrial fibrillation and heart failure.

Dysfunction. J Am Coll Cardiol. 1998;31 (4):749–753.

Am Heart J. 2006;152 (5):974. e7–11.

308.

Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral

332.

Kovoor P, Eipper V, Byth K et al. Comparison of sotalol with

anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel

amiodarone for long-term treatment of spontaneous sustained

Trial with Irbesartan for prevention of Vascular Events (ACTIVE W):

ventricular tachyarrhythmia based on coronary artery disease. Eur

a randomised controlled trial. Lancet. 2006;367 (9526):1903–1912.

Heart J. 1999;20 (5):364–374.

309.

Cleland JG, Coletta AP, Lammiman M et al. Clinical trials update from the

333.

Беленков Ю.Н., Сангонова Д.Ф., Агеев Ф.Т., Мареев В.Ю. Сравни-

European Society of Cardiology meeting 2005: CARE–HF extension

тельное исследование длительного применения соталола, метопроло-

study, ESSENTIAL, CIBIS–III, S–ICD, ISSUE–2, STRIDE–2, SOFA,

ла и амиодарона у больных с тяжелой сердечной недостаточностью

IMAGINE, PREAMI, SIRIUS–II and ACTIVE. Eur J Heart Fail. 2005;7

и прогностически опасными желудочковыми нарушениями ритма

(6):1070–1075.

сердца. Кардиология, 1996;36 (1):37–48.

310.

HylekEM,GoAS,ChangYetal.EffectofIntensityofOralAnticoagulation

334.

MacNeil JH. Review of Sotalol safety in 3257 patients with arrhythmias after

on Stroke Severity and Mortality in Atrial Fibrillation. N Engl J Med.

15 June. 1991. Bristol Myers Squibb report, 1993. Data on file.

2003;349 (11):1019–1026.

335.

Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N Engl

311.

Baker DW, Wright RF. Management of heart failure, IV: anticoagulation

J Med. 1999;341 (12):910–911.

for patients with heart failure due to left ventricular systolic dysfunction.

336.

Dries DL, Exner DV, Gersh BJ et al. Atrial fibrillation is associated

JAMA. 1994;272 (20):1614–1618.

with an increased risk for mortality and heart failure progression in patients

312.

Dries DL, Domanski MJ, Waclawiw MA et al. Effect of antithrombotic

with asymptomatic and symptomatic left ventricular systolic dysfunction: a

therapy on risk of sudden coronary death in patients with congestive heart

retrospective analysis of the SOLVD trials: Studies of Left Ventricular

failure. Am J Cardiol. 1997;79 (7):909–913.

Dysfunction. J Am Coll Cardiol. 1998;32 (3):695–703.

313.

Singer DE, Chang Y, Fang MC et al. Should Patient Characteristics

337.

Pardaens K, Van Cleemput J, Vanhaecke J, Fagard RH. Atrial fibrillation is

Influence Target Anticoagulation Intensity for Stroke Prevention

associated with a lower exercise capacity in male chronic heart failure

in Nonvalvular Atrial Fibrillation?: The ATRIA Study. Circ Cardiovasc

patients. Heart. 1997;78 (6):564–568.

Qual Outcomes. 2009;2 (4):297–304.

338.

Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for

314.

Carson P, Ziesche S, Johnson G, Cohn JN, for the Vasodilator-Heart

the management of patients with atrial fibrillation. A report of the American

Failure Trial Study Group. Racial differences in response to therapy for

College of Cardiology/American Heart Association Task Force on Practice

heart failure: analysis of the vasodilator-heart failure trials. J Card Fail.

Guidelines and the European Society of Cardiology Committee for Practice

1999;5 (3):178–187.

Guidelines and Policy Conferences (Committee to develop guidelines for the

315.

Шарашидзе М.Л., Мареев В.Ю., Суворов Ю.И. и др. Влияние изо-

management of patients with atrial fibrillation) developed in collaboration

сорбида динитрата на водные пространства организма при хрони-

with the North American Society of Pacing and Electrophysiology. Eur

ческой недостаточности кровообращения. Тер. архив. 1989;61

Heart J. 2001;22 (20):1852–1923.

(6):119–122.

339.

Wyse DG, Waldo AL, DiMarco JP et al. The Atrial Fibrillation Follow-up

316.

Packer M, O’Connor CM, Ghali JK et al. Effect of amlodipine on

Investigation of Rhythm Management (AFFIRM) Investigators. A

morbidity and mortality in severe chronic heart failure. Prospective

comparison of rate control and rhythm control in patients with atrial

Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med.

fibrillation. N Engl J Med. 2002;347 (23):1825–1833.

1996;335 (15):1107–1114.

340.

Van Gelder IC, Hagens VE, Bosker HA et al. Rate Control versus Electrical

317.

O’Connor CM, Carson PE, Miller AB et al. Effect of amlodipine on mode

Cardioversion for Persistent Atrial Fibrillation (RACE) Study Group. N Engl

of death among patients with advanced heart failure in the PRAISE trial.

J Med. 2002;347 (23):1834–1840.

Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol.

341.

Boos CJ, Carlsson J, More RS. Rate or rhythm control in persistent atrial

1998;82 (7):881–887.

fibrillation? QJM. 2003;96 (12):881–892.

318.

Kanel WB, Plehn JF, Cupples LA. Cardiac failure and sudden death

342.

Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest

in the Framingham Study. Am Heart J. 1988;115 (4):869–875.

effective intensity of prophylactic anticoagulation in for patients with

319.

Luu M, Stevenson WG, Stevenson LW et al. Diverse mechanisms

nonrheumatic atrial fibrillation. N Engl J Med. 1996;335 (8):540–546.

of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80

343.

Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic treatment

(6):1675–1680.

to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann

320.

Мареев В.Ю. Сердечная недостаточность и желудочковые наруше-

Intern Med. 1999;131 (7):492–501.

ния ритма сердца: проблема лечения. Кардиология. 1996;36 (12):4–

344.

Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM

12

substudy of the first antiarrhythmic drug. AFFIRM First Antiarrhythmic

321.

Hjalmarson A, Goldstein S, Fagerberg B, et al, for the MERIT–HF Study

Drug Substudy Investigators. J Am Coll Cardiol. 2003;42 (1):20–29.

Group. Effects of controlled-release metoprolol on total mortality,

345.

Letelier LM, Udol K, Ena J et al. Effectiveness of amiodarone for conversion

hospitalizations, and well-being in patients with heart failure: the

of atrial fibrillation to sinus rhythm. Arch Intern Med. 2003;163 (7):777–

Metoprolol CR/XL Randomized Intervention Trial in congestive heart

785.

failure (MERIT-HF). JAMA. 2000;283 (10):1295–302.

346.

Naccarelli GV, Rinkenberger RL, Dougherty AH, Fitzgerald DM. Adverse

322.

Poole-Wilson PA, Uretsky BF, Thygesen K et al. Mode of death in heart

effects of amiodarone: pathogenesis, incidence and management. Med

failure: findings from the ATLAS trial. Heart. 2003;89 (1):42–48.

Toxicol Adverse Drug Exp. 1989;4 (4):246–253.

323.

Казей Д.В., Мареев В.Ю., Мухарлямов Н.М. Влияние изменений

347.

Greene HL, Graham EL, Werner JA et al. Toxic and therapeutic effects

гемодинамики на нарушения ритма сердца: опыт длительного внут-

of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol.

ривенного введения раствора нитроглицерина больным с сердечной

1983;2 (6):1114–1128.

недостаточностью. Бюлл. Всесоюзн. кардиол. научн. Центра.

348.

Roy D, Talajic M, Dorian P, Connolly S et al. Amiodarone to prevent

1989;2:20–25.

recurrence of atrial fibrillation. Canadian Trial of atrial Fibrillation

324.

Казей Д.В., Мареев В.Ю., Агеев Ф.Т. и др. Влияние периферических

Investigators. N Engl J Med. 2000;342 (13):913–920.

вазодилататоров на нарушения ритма сердца у больных с хроничес-

349.

Lundstrom T, Ryden L. Chronic atrial fibrillation. Long-term results of direct

кой сердечной недостаточностью. Кардиология. 1992;32, (4):30–34

current cardioversion. Acta Med Scand. 1988;223 (1):53–59.

325.

Myerburg RJ, Mitrani R, Interian A et al. Interpretation of outcomes

350.

Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with

of antiarrhythmic clinical trials: design features and population impact.

angiotensin-converting enzyme inhibitors and angiotensin receptor blockers:

Circulation. 1998;97 (15):1514–1521.

a meta-analysis. J Am Coll Cardiol. 2005;45 (11):1832–1839

326.

CIBIS III trial: bisoprolol treatment for CHF leads to 46% reduction

351.

Matsuda M, Matsuda Y, Yamagishi T et al. Effects of digoxin, propranolol,

in sudden death after one year. Cardiovasc J S Afr. 2006;17 (5):278.

and verapamil on exercise in patients with chronic isolated atrial fibrillation.

327.

Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic

Cardiovasc Res. 1991;25 (6):453–457.

amiodaroneonmortalityafteracuremyocardial infarction and incongestive

352.

David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis

heart failure: meta-analysis of individual data from 6500 patients

in the control of heart rate in patients with chronic atrial fibrillation: beneficial

in randomized trials. Lancet. 1997;350 (9089):1417–1424.

effect of an added beta adrenergic blocking agent. Am J Cardiol. 1979;44

328.

Мареев В.Ю. Возможно ли успешное предотвращение внезапной

(7):1378–1382.

смерти у больных с хронической сердечной недостаточностью и дис-

353.

Farshi R, Kistner D, Sarma JS et al. Ventricular rate control in chronic atrial

функциейлевогожелудочка.Препаратыилиаппараты?Кардиология.

fibrillation during daily activity and programmed exercise: a crossover open-

2004;42 (12):4–15.

label study of five drug regimens. J Am Coll Cardiol. 1999;33 (2):304–310.

329.

Boutitie F, Boissel JP, Connolly SJ et al. Amiodarone Interaction

354.

Khand AU, Rankin AC, Martin W et al. Carvedilol alone or in combination

With β-Blockers. Analysis of the Merged EMIAT (European Myocardial

with digoxin for the management of atrial fibrillation in patients with heart

Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone

failure? J Am Coll Cardiol. 2003;42 (11):1944–1951.

Myocardial Infarction Trial) Databases. Circulation. 1999;99 (17):2268–

355.

Davie AP, Love MP, McMurray JJ. Even low-dose aspirin inhibits

2275.

arachidonic acid-induced vasodilation in heart failure. Clin Pharmacol Ther.

330.

Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable

2000;67 (5):530–537

cardioverter-defibrillator for congestive heart failure. N Engl J Med.

356.

Guazzi M, Pontone G, Agostoni P. Aspirin worsens exercise performance

2005;352 (3):225–237.

and pulmonary gas exchange in patients with heart failure who are taking

angiotensin-converting enzyme inhibitors. Am

Heart

J. 1999;138

(ФЛАГ, ФАСОН, ФАГОТ). Журнал Сердечная Недостаточность.

(2 Pt 1):254–260.

2003;4 (5):261–265.

357.

Атауллаханова Д.М., Мареев В.Ю. Влияние лазикса на центральную

382.

Cleland JGF. The perindopril in elderly people with chronic heart failure

гемодинамику у больных с сердечной недостаточностью. Тер. Арх.

(PEP-CHF) study. Hot Line I Session

on XVth World Congress

1980;60 (11):109–112.

of Cardiology, Barcelona, 03 September 2006.

358.

Jhunds PS, Davie AP, McMurray JJ. Aspirin inhibits the acute venodilator

383.

Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of

response to furosemide in patients with chronic heart failure. J Am Coll

treatment on left ventricular mass in essential hypertension. Am J Med.

Cardiol. 2001;37 (5):1234–1238.

2003;115 (1):41–46.

359.

Lindfeld JA, Robertson AD, Lowes BD et al. Aspirin impairs reverse

384.

Мареев В.Ю., Овчинников А.Г., Агеев Ф.Т., Беленков Ю.Н.

myocardial remodeling in patients with heart failure treated with beta-

Влияние ингибиторов АПФ и антагонистов рецепторов к ангиотен-

blockers. J Am Coll Cardiol. 2001;38 (7):1950–1956.

зину-II на диастолическую функцию левого желудочка у пациентов

360.

A randomized, blinded, trial of clopidogrel vs aspirin in patients at risk of

с относительно сохранной систолической функцией левого желу-

ischemicevents(CAPRIE).CAPRIESteeringCommittee.Lancet.1996;348

дочка: результаты исследования «Периндоприл,

ИРбесартан

(9038):1329–1339.

и АмлодипиН у болЬных с ХСН и сохраненной систолической фун-

361.

Yusuf S, Zhao F, Mehta S. R et al. Effects of clopidogrel in addition to aspirin

кцией левого желудочка (ПИРАНЬя). Журнал Сердечная

in patients with acute coronary syndromes without ST-segment elevation. N

Недостаточность. 2005;6 (1):4–14.

Engl J Med. 2001;345 (7):494–502.

385.

Bergstrom A, Anersson B, Ender M et al. Effect of carvedilol on diastolic

362.

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised

function in patients with diastolic heart failure and preserved systolic

trialists of antiplatelet therapy, I: prevention of death, myocardial infarction,

function. Results of the Swedish Doppler-echocardiographic study

and stroke by prolonged antiplatelet therapy in various categories of patients.

(SWEDIC). Eur J Heart Fail. 2004;6 (4):453–461.

BMJ. 1994;308 (6921):81–106.

386.

Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the

363.

Cleland JGF. Aspirin: does it have a role in the treatment of heart failure due

effect of nebivolol on mortality and cardiovascular hospital admission in

to ischemic heart disease? In book.: Coats A.

(ed)

Controversies

elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26

in the management of heart failure. Churchill Livingstone. 1997:69–82

(3):215–225.

364.

Hayden M, Pigone M, Phillips et al. Aspirin for primary prevention of

387.

The Danish Study Group on Verapamil in Myocardial Infarction. Secondary

cardiovascular events: a summary of the evidence for U.S. Preventive

prevention with verapamil after myocardial infarction. Am J Cardiol. 1990;66

Services Task Force. Ann Intern Med. 2002;136 (2):161–172

(21):33I–40I.

365.

Peterson JG, Topol EJ, Sapp SK et al. Evaluation of the effect of aspirin

388.

Lopez B, Querejrta R, Gonzalez A et al. Effects of loop diuretics on

combined with angiotensin-converting enzyme inhibitors in patients

myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am

with coponary artery disease. Am J Med. 2000;109 (5):371–377.

Coll Cardiol. 2004;43 (11):2028–2035.

366.

Latini R, Tognioni G, Maggioni AP et al. Clinical effects of early angiotensin-

389.

Ali Ahmed, Rich MW, Love TE et al. Digoxin and reduction in mortality and

converting enzyme inhibitor treatment for acute myocardial infarction are

hospitalization in heart failure: a comprehensive post hoc analysis of the DIG

similar in presence ana absence of aspitin: systematic overview of individual

trial. Eur Heart J. 2006;27 (2):178–186.

data from 96712 randomized patients. Angiotensin-converting Enzyme

390.

Рекомендации Всероссийского научного общества специалистов

Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol.

по клинической электрофизиологии, аритмологии и кардиостимуля-

2000;35 (7):1801–1807.

ции по проведению клинических электрофизиологических исследо-

367.

Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in

ваний, катетерной абляции и имплантации антиаритмических уст-

patients with heart failure or left ventricular dysfunction: a systematic

ройств. http://cardio.tomsk.ru/recom. pdf.

overview of data from individual patients. ACE-inhibitor Myocardial

391.

РевишвилиА.Ш.,АнтонченкоИ.В.,АрадашевА.В.идр.Клинические

Infarction Collaborative Group. Lancet. 2000;355 (9215):1575–1581.

Рекомендации по применению электрокардиостимуляторов, имплан-

368.

Takkouche, Etminan M, Caamano F et al. Interaction between aspirin

тируемых кардиовертеров-дефибрилляторов, устройств для сердеч-

andACEinhibitors:resolvingdiscrepanciesusingameta–nalysis.Interaction

ной ресинхронизирующей терапии и имплантируемых кардиомони-

between aspirin and ACE Inhibitors: resolving discrepancies using a meta-

торов. ВНОА. Новая редакция. Москва 2009, с. 13–146.

analysis. Drug Saf. 2002;25 (5):373–378.

392.

European Heart Rhythm Association; Heart Rhythm Society; Zipes DP,

369.

Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone

Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 guidelines for

in severe chronic heart failure: results of a multicenter study in the United

management of patients with ventricular arrhythmias and the prevention

States. Am Heart J. 1991;121:1956–1964.

of sudden cardiac death-executive summary. J Am Coll Cardiol. 2006;48 (5):

370.

Hatzizacharias A, Makris T, Krespi P et al. Intermittent milrinone effect

e247–346.

on long-term hemodynamic profile in patients with severe congestive heart

393.

Bristow M, Saxon L, Boehmer J et al. Comparison of Medical Therapy,

failure. Am Heart J. 1999;138:241–246.

Pacing and Defibrillation in Heart Failure (COMPANION) Investigators.

371.

Uretsky BF, Jessup M, Konstam MA et al, for the Enoximone Multicenter

Cardiac-resynchronization therapy with or without an implantable

Trial Group. Multicenter trial of oral enoximone in patients with moderate to

defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May

moderately severe congestive heart failure: lack of benefit compared with

20;350 (21):2140–2150.

placebo. Circulation. 1990;82 (3):774–780.

394.

Cleland J, Daubert J, Erdmann E et al. Cardiac Resynchronization-Heart

372.

Feldman AM, Bristow MR, Parmley WW et al, for the Vesnarinone Study

Failure (CARE-HF) Study Investigators. The effect of cardiac

Group. Effects of vesnarinone on morbidity and mortality in patients

resynchronization on morbidity and mortality in heart failure. N Engl J Med.

with heart failure. N Engl J Med. 1993;329 (3):149–155.

2005;352 (15):1539–1549.

373.

Packer M, Carver JR, Rodeheffer RJ et al, for the PROMISE Study

395.

Abraham W, Young J, Leon A et al. Multicenter InSync ICD II Study

Research Group. Effect of oral milrinone on mortality in severe chronic heart

Group. Effects of cardiac resynchronization on disease progression in patients

failure. N Engl J Med. 1991;325 (21):1468–1475.

with left ventricular systolic dysfunction, an indication for an implantable

374.

Applefeld MM, Newman KA, Sutton FJ et al. Outpatient dobutamine

cardioverter-defibrillator, and mildly symptomatic chronic heart failure.

and dopamine infusions in the management of chronic heart failure: clinical

Circulation. 2004;110 (18):2864–2868.

experience in 21 patients. Am Heart J. 1987;114 (3):589–595.

396.

Lee D, Green L, Liu P et al. Effectiveness of implantable defibrillators for

375.

Elis A, Bental T, Kimchi O, Ravid M, Lishner M. Intermittent dobutamine

preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol.

treatment in patients with chronic refractory congestive heart failure: a

2003;41 (9):1573–1582.

randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther.

397.

A comparison of antiarrhythmic-drug therapy with implantable defibrillators

1998;63 (6):682–685.

in patients resuscitated from near-fatal

ventricular

arrhythmias.

376.

Caffe MS, Califf RM, Adams KF et al. Short-term intravenous milrinone for

The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators.

acute exacerbation of chronic heart failure: a randomized controlled trial.

N Engl J Med. 1997;337 (22):1576–1583.

JAMA. 2002;287 (12):1541–1547.

398.

Kadish A, Dyer A, Daubert J et al. Prophylactic defibrillator implantation in

377.

Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis

patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350

and treatment of chronic heart failure. Eur Heart J. 2005;26 (11):1115–

(21):2151–2158.

1140.

399.

Moss A, Hall W, Cannom D et al. Improved survival with an implanted

378.

Moiseev VS, Poder P, Andrejevs N et al. Safety and efficacy of a novel

defibrillator in patients with coronary disease at high risk for ventricular

calcium sensitizer, levosimendan, in patients with left ventricular failure due

arrhythmia. Multicenter Automatic Defibrillator Implantation Trial

to an acute myocardial infarction. A randomized, placebo-controlled,

Investigators. N Engl J Med. 1996;335 (26) :1933–1940.

double-blind study (RUSSLAN). Eur Heart J. 2002;23 (18):1422–1432.

400.

Buxton A, Lee K, Fisher J et al. A randomized study of prevention of sudden

379.

Диагностика и лечение фибрилляции предсердий. Российские реко-

death in patients with coronary artery disease. Multicenter Unsustained

мендации. Разработаны Комитетом экспертов ВНОК. Москва. 2005.

Tachycardia Trial Investigators. N Engl J Med. 1999;341 (25):1882–1890.

380.

Philbin EF, Rocco TA. Use of angiotensin-converting enzyme inhibitors in

401.

Moss A, Zareba W, Hall W et al. Prophylactic implantation of a defiblirillator

heart failure with preserved ventricular systolic function. Am Heart J.

in patients with myocardial infarction and reduced ejection fraction. N Engl

1997;134 (2 Pt 1):188–195.

J Med. 2002;346 (12):877–883.

381.

Карпов Ю.А., Мареев В.Ю., Чазова И.Е. Российские программы

402.

Rose EA, Gelijns AC, Moskowitz AJ. Long-term mechanical left ventricular

оценки эффективности лечения фозиноприлом больных с артериаль-

assistance for end-stage heart failure. N Engl J Med. 2001;345 (20):1435–

ной гипертонией и сердечной недостаточностью. Проект ТРИ Ф

1443.